




RealRate

PHARMACEUTICAL 2020

PLx Pharma Inc.
Rank 289 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of PLx Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PLx Pharma Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 68% points. The greatest weakness of PLx Pharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 184% points.

The company's Economic Capital Ratio, given in the ranking table, is -460%, being 157% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	14,283
Cost of Goods Sold	0
Intangible Assets	2,061
Liabilities, Current	6,093
Liabilities, Non-Current	1,032
Other Assets	692
Other Compr. Net Income	0
Other Expenses	6,705
Other Liabilities	9,808
Other Net Income	405
Property and Equipment	1,467
Research and Development	4,741
Revenues	565
Selling, General and Administrative Expense	10,027

Output Variable	Value in 1000 USD
Assets	18,503
Liabilities	16,933
Expenses	21,473
Stockholders Equity	1,570
Net Income	-20,502
Comprehensive Net Income	-20,502
Economic Capital Ratio	-460%